STAT reports that the FDA has ended the fast-track drug review initiative started in June 2025 under former Commissioner Marty Makary. No further details on the reasons or next steps were provided.
This decision could slow approval processes for new drugs, which matters for pharma and biotech executives managing regulatory risk and market entry. Companies should monitor for further guidance from the FDA.
